Aim: Graves' disease is an autoimmune thyroid disease that is the most common cause of hyperthyroidism. Peripheral blood cell parameters such as neutrophils, lymphocytes, and platelets play a role in inflammation control. Several studies have proven that neutrophil-lymphocyte ratio, monocyte-lymphocyte ratio and platelet-lymphocyte ratio are indicators of chronic subclinical inflammation in various diseases. In our study, we aimed to review the peripheral blood picture by evaluating these parameters before and after antithyroid treatment in patients with Graves' disease. Patients and methods: A total of 120 patients (93 female, 27 male) between the ages of 18-65 were included. Demographic data, hemogram and biochemical data of the patients were recorded retrospectively at the time of diagnosis and after euthyroidism was achieved with medical treatment. Results: During the treatment, there was an increase in hemoglobin, lymphocytes, neutrophils and red cell distribution width, while a decrease in monocytes was observed. There was no significant difference between white blood cell, platelet and mean platelet volume. In addition, while there was no statistically significant difference between neutrophil-lymphocyte ratio (p = 0.8) and thrombocyt-lymphocyte ratio (p = 0.078) after euthyroid state, a statistically significant difference was found in favor of a decrease in monocyte-lymphocyte ratio (p = 0.006). Conclusion: Changes in hematopoiesis are relatively common in patients with newly diagnosed Graves' disease, and initiation of antithyroid therapy leads to improvement in these parameters. Although neutrophil-lymphocyte ratio, monocyte-lymphocyte ratio and platelet-lymphocyte ratio are accepted as new, non-invasive markers in clinical evaluation, in our study only a significant decrease in monocyte-lymphocyte ratio levels was observed after euthyroidism was achieved with antithyroid treatment.
References
1.
Dorgalaleh A, Mahmoodi M, Varmaghani B. Effect of thyroid dysfunctions on blood cell count and red blood cell indice. Iran J Ped Hematol Oncol. 2013;2013;3(2):73-7.
2.
McGregor AM, Petersen MM, McLachlan SM, Rooke P, Smith BR, Hall R. Carbimazole and the Autoimmune Response in Graves’ Disease. New England Journal of Medicine. 1980;303(6):302–7.
3.
Dasgupta R, Atri A, Jebasingh F, Hepzhibah J, Christudoss P, Asha H, et al. Platelet-Lymphocyte Ratio as a Novel Surrogate Marker to Differentiate Thyrotoxic Patients with Graves Disease from Subacute Thyroiditis: a Cross-Sectional Study from South India. Endocrine Practice. 2020;26(9):939–44.
4.
Wenisch C, Myskiw D, Gessl A, Graninger W. Circulating selectins, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in hyperthyroidism. The Journal of Clinical Endocrinology & Metabolism. 1995;80(7):2122–6.
5.
Chhabra S, Tenorio G. Thrombotic thrombocytopenic purpura precipitated by thyrotoxicosis. Journal of Clinical Apheresis. 2012;27(5):265–6.
6.
Ushiki T, Masuko M, Nikkuni K, Terukina-Yoshida J, Momotsu-Nanba A, Morikawa H, et al. Successful Remission of Evans Syndrome Associated with Graves’ Disease by Using Propylthiouracil Monotherapy. Internal Medicine. 2011;50(6):621–5.
7.
Schmohl J, Vogel W, Gallwitz B, Möhle R. Thrombozytopenie bei Morbus Basedow. DMW - Deutsche Medizinische Wochenschrift. 2012;137(20):1056–1056.
8.
Celik T. Neutrophil-to-lymphocyte ratio in thyroid ophthalmopathy. Bratislava Medical Journal. 2017;118(08):495–8.
9.
Turan E. Evaluation of neutrophil-to-lymphocyte ratio and hematologic parameters in patients with Graves’ disease. Bratislava Medical Journal. 2019;120(06):476–80.
10.
Rydzewska M, Jaromin M, Pasierowska IE, Stożek K, Bossowski A. Role of the T and B lymphocytes in pathogenesis of autoimmune thyroid diseases. Thyroid Research. 2018;11(1).
11.
Szydełko J, Litwińczuk M, Szydełko M, Matyjaszek-Matuszek B. Neutrophil-to-Lymphocyte, Monocyte-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Relation to Clinical Parameters and Smoking Status in Patients with Graves’ Orbitopathy—Novel Insight into Old Tests. Journal of Clinical Medicine. 9(10):3111.
12.
Dağdeviren M, Akkan T, Yapar D, Karakaya S, Dağdeviren T, Ertuğrul D, et al. Can Neutrophil/Lymphocyte Ratio Be Used as an Indicator of Inflammation in Patients with Hyperthyroidism? Journal of Medical Biochemistry. 2019;0(0).
13.
Peng Y, Qi Y, Huang F, Chen X, Zhou Y, Ye L, et al. Down-regulated resistin level in consequence of decreased neutrophil counts in untreated Grave’s disease. Oncotarget. 2016;7(48):78680–7.
14.
Cooper DS. Antithyroid Drugs. New England Journal of Medicine. 2005;352(9):905–17.
15.
Kurata Y, Nishiōeda Y, Tsubakio T, Kitani T. Thrombocytopenia in Graves’ Disease: Effect of T<sub>3 </sub>on Platelet Kinetics. Acta Haematologica. 1980;63(4):185–90.
16.
Menconi F, Marcocci C, Marinò M. Diagnosis and classification of Graves’ disease. Autoimmunity Reviews. 2014;13(4–5):398–402.
17.
Kawa MP, Grymuła K, Paczkowska E, Baśkiewicz-Masiuk M, Dąbkowska E, Koziołek M, et al. Clinical relevance of thyroid dysfunction in human haematopoiesis: biochemical and molecular studies. European Journal of Endocrinology. 2010;162(2):295–305.
18.
Geetha JP, Srikrishna R. Role of red blood cell distribution width (rdw) in thyroid dysfunction. Int J Biol Med Res. 2012;3:1476–8.
19.
Reddy J, Brownlie BE, Heaton DC, Hamer JW, Turner JG. The peripheral blood picture in thyrotoxicosis. N Z Med J. 1981;93(679):6940035.
20.
Artemniak-Wojtowicz D, Witkowska-Sędek E, Borowiec A, Pyrżak B. Peripheral blood picture and aminotransferase activity in children with newly diagnosed Graves’ disease at baseline and after the initiation of antithyroid drug therapy. Central European Journal of Immunology. 2019;44(2):132–7.
21.
Hambsch K, Herrmann F, Fischer H, Langpeter D, Mäller P, Sorger D. Blutbildveränderungen bei Hyperthyreose [Changes in the blood picture in hyperthyroidism. Z Gesamte Inn Med. 1989;44(10):300–6.
22.
Ford HC, Carter JM. The haematology of hyperthyroidism: abnormalities of erythrocytes, leucocytes, thrombocytes and haemostasis. Postgraduate Medical Journal. 1988;64(756):735–42.
23.
Shaikh H, Kamran A, Shaikh S, Mewawalla P. Aplastic anemia secondary to propylthiouracil: A rare and life-threatening adverse effect. Journal of Oncology Pharmacy Practice. 2019;25(3):715–8.
24.
Prasek K, Płazińska MT, Królicki L. Diagnosis and treatment of Graves’ disease with particular emphasis on appropriate techniques in nuclear medicine. General state of knowledge. Nuclear Medicine Review. 18(2):110–6.
25.
Shi L, Qin X, Wang H, Xia Y, Li Y, Chen X, et al. Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma. Oncotarget. 2017;8(12):18792–801.
26.
Lee YH, Song GG. Neutrophil‐to‐lymphocyte ratio, mean platelet volume and platelet‐to‐lymphocyte ratio in Behçet’s disease and their correlation with disease activity: A meta‐analysis. International Journal of Rheumatic Diseases. 2018;21(12):2180–7.
27.
Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N, et al. Comparison of Methimazole and Propylthiouracil in Patients with Hyperthyroidism Caused by Graves’ Disease. The Journal of Clinical Endocrinology & Metabolism. 2007;92(6):2157–62.
28.
Prabhakar BS, Bahn RS, Smith TJ. Current Perspective on the Pathogenesis of Graves’ Disease and Ophthalmopathy. Endocrine Reviews. 2003;24(6):802–35.
29.
Salvi M, Pedrazzoni M, Girasole G, Giuliani N, Minelli R, et al. Serum concentrations of proinflammatory cytokines in Graves’ disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. European Journal of Endocrinology. 2000;197–202.
30.
Wémeau JL, Klein M, Sadoul JL, Briet C, Vélayoudom-Céphise FL. Graves’ disease: Introduction, epidemiology, endogenous and environmental pathogenic factors. Ann Endocrinol (Paris. 2018;0003-4266 18 31245-9.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
